Currently Recruiting Trials – Breast Cancer

Vaccines

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy. St. Louis, Missouri. Estimated primary completion date: August 2019.
NCT02427581

Pilot Trial of a Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer. Cleveland, Ohio. Estimated primary completion date: June 2018.
NCT02479230

Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer. Dallas, Texas. Estimated primary completion date: March 2017.
NCT02018458

A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients. Seattle, Washington. Estimated primary completion date: October 2016.
NCT02157051

A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy. St. Louis, Missouri. Estimated primary completion date: June 2019.
NCT02348320

A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer. Philadelphia, Pennsylvania. Estimated primary completion date: June 2018.
NCT01660529

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab. Duarte, California. Estimated primary completion date: November 2016.
NCT02432963

Leave a Comment

Required fields are marked *.